Enzalutamide
Enzalutamide is a next-generation androgen receptor antagonist that competitively inhibits AR with ~8-fold greater affinity than bicalutamide, and additionally blocks AR nuclear translocation and DNA binding. It remains active in cells with AR overexpression that convert bicalutamide into a partial agonist. FDA-approved for metastatic castration-sensitive and castration-resistant prostate cancer.
Description
Scientific Overview: Enzalutamide is a next-generation androgen receptor antagonist that competitively inhibits AR with ~8-fold greater affinity than bicalutamide, and additionally blocks AR nuclear translocation and DNA binding. It remains active in cells with AR overexpression that convert bicalutamide into a partial agonist. FDA-approved for metastatic castration-sensitive and castration-resistant prostate cancer.
Mechanism of Action: Androgen Receptor (AR) Antagonist / Nuclear Import Inhibitor
Purity: ≥99% | Molecular Formula: C21H16F4N4O2S
For Research Use Only. Not intended for diagnostic, therapeutic, or clinical applications.
Additional information
| Effect | Androgen Receptor (AR) Antagonist / Nuclear Import Inhibitor |
|---|---|
| Purity | ≥99% |
| Molecular Formula | C21H16F4N4O2S |
| CAS Number | 915087-33-1 |
